Catalyst Wire Dossier Catalyst Wire Dossier

IgPro20

intravenous immunoglobulin 20% solution · CSL Behring
Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for IgPro20, covering 2018-07-05 to 2026-04-22. Get the full timeline:

Most recent: Clinical Trial Update: An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID) [Phase 4]

See pricing